Publisher: Medscape


Shore Up Systems to Optimize Sepsis Outcomes

In the Media Icon

Hospital-based systems-level sepsis interventions in diagnostic testing, antimicrobial stewardship, and program infrastructure can improve outcomes across the continuum of care, according to a new position paper from the Infectious Diseases Society of America (IDSA) and other medical organizations.


Antibiotic Overuse Persists in Complicated Community-Acquired Pneumonia

In the Media Icon

Approximately half of children with complicated community-acquired pneumonia (cCAP) receive antibiotics for methicillin-resistant Staphylococcus aureus despite low positivity rates, based on data from a new study presented at the Pediatric Hospital Medicine (PHM) 2026 conference.


Candida auris Infections Persist in Clinical and Screening Settings

In the Media Icon

Candida auris infections in healthcare settings increased overall between 2022 and 2024, according to data from a new surveillance summary of approximately 40,000 cases published by the CDC.


Q&A: Managing GI Toxicities of Immunotherapy

In the Media Icon

Immune checkpoint inhibitors (ICIs) have been transformative in the treatment of certain cancers, but as use of the drugs continues to climb, so do the ranks of patients dealing with gastrointestinal (GI) side effects.


When Your Loved Ones Trust TikTok Over Their Doctor — and You

In the Media Icon

Recently, Quincy Harberger, MD, found himself discussing cardiovascular disease with his uncle.


Do We Need to Rethink MS Classification?

In the Media Icon

Welcome to Medscape. I’m your host, Dr. Andrew Wilner.


Drug-Resistant Shigella Surges in Adult Men

In the Media Icon

Cases of extensively drug-resistant (XDR) Shigella, for which no approved treatment is available, increased significantly between 2011 and 2023, based on data from approximately 17,000 isolates.


The Ethics of Referring Patients to the Hospital Pharmacy

In the Media Icon

As an increasing number of physicians leave private practice to work for hospitals or private equity firms, the risk of conflicts of interest increases.